Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 9;16:923–935. doi: 10.2147/OTT.S427942

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Chen et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Kaplan-Meier survival curves were plotted to analyze the overall survival (OS) of patients with pancreatic cancer who received a combination of gemcitabine plus nab-paclitaxel (GnP) chemotherapy and immunotherapy, stratified by different clinical subgroup. (A) OS according to the hepatic metastasis (yes vs no, p < 0.001). (B) OS according to the treatment cycles (<= 6 cycles vs >6 cycles, p = 0.008). (C) OS according to the Eastern Cooperative Oncology Group (ECOG) performance status (PS) (0 vs 1, p = 0.003). (D) OS according to the sex (male vs female, p = 0.776). (E) OS according to the age (<= 62y vs >62y, p = 0.163). (F) OS according to the carbohydrate antigen 19–9 (CA19-9) level (high vs low, p = 0.518). (G) OS according to the carcinoembryonic antigen (CEA) level (high vs low, p = 0.851). (H) OS according to the tumor location (body and tail of pancreas vs pancreatic head, p = 0.950).